Prescription drug · BLA
Hadlima (adalimumab-bwwd) NDC 78206-186
Adalimumab 40 mg/.4mL · Solution · Subcutaneous · Organon LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 78206-186-01 | 78206018601 | 2 SYRINGE in 1 CARTON (78206-186-01) / .4 mL in 1 SYRINGE (78206-186-99)Marketed from Jul 1, 2023 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Hadlima
- Generic name (nonproprietary)
- adalimumab-bwwd
- Active ingredients
- Adalimumab — 40 mg/.4mL
- Dosage form
- Solution
- Route
- Subcutaneous
- Labeler
- Organon LLC
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761059
- Marketing start
- Listing expires
- Other FDA classes
- Monoclonal (Chemical structure)Tumor Necrosis Factor Receptor Blocking Activity (Mechanism)
- Identifiers
- Product ID 78206-186_28a18c27-7052-4b4d-af4e-d81048f424e8SPL ID 28a18c27-7052-4b4d-af4e-d81048f424e8
- Pharmacologic class
- Tumor Necrosis Factor Blocker
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeMed-Code curated
J0135 — Injection, adalimumab, 20 mg
Billing unit: 20 mg. Units on the claim = dose given ÷ 20 mg.
Adalimumab is usually self-administered and dispensed through a pharmacy benefit. Adalimumab biosimilars are listed under their own names.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N478206018601followed by a unit qualifier and the quantityPackage 78206-0186-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
The FDA listing for this product does not reference a label (SPL) set.
Other NDCs under BLA 761059
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Hadlimaadalimumab-bwwd | Adalimumab 40 mg/.8mL | SolutionSubcutaneous | A-S Medication Solutions | 50090-6705 |
| Hadlimaadalimumab-bwwd | Adalimumab 40 mg/.8mL | SolutionSubcutaneous | A-S Medication Solutions | 50090-6706 |
| Hadlimaadalimumab-bwwd | Adalimumab 40 mg/.4mL | SolutionSubcutaneous | A-S Medication Solutions | 50090-6707 |
| Hadlimaadalimumab-bwwd | Adalimumab 40 mg/.8mL | SolutionSubcutaneous | Organon LLC | 78206-185 |
| Hadlimaadalimumab-bwwd | Adalimumab 40 mg/.8mL | SolutionSubcutaneous | Organon LLC | 78206-183 |
| Hadlimaadalimumab-bwwd | Adalimumab 40 mg/.8mL | SolutionSubcutaneous | Organon LLC | 78206-184 |
| Hadlimaadalimumab-bwwd | Adalimumab 40 mg/.4mL | SolutionSubcutaneous | Organon LLC | 78206-187 |
| Adalimumab-bwwd | Adalimumab 40 mg/.4mL | SolutionSubcutaneous | Cordavis Limited | 83457-187 |
| Adalimumab-bwwd | Adalimumab 40 mg/.4mL | SolutionSubcutaneous | Cordavis Limited | 83457-186 |
- Source
- FDA NDC Directory via openFDA; Med-Code HCPCS directory (curated)
- openFDA data updated
Med-Code stores this record for up to 24 hours before requesting it again.
Reference information only. Verify codes and billing rules against the applicable payer and official source before submitting a claim. How Med-Code handles data.